ipilimumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
human origin 4958 477202-00-9

Description:

MoleculeDescription

Synonyms:

  • ipilimumab
  • yervoy
  • MDX-010
  • MDX-CTLA-4
  • ipilimumab (genetical recombination)
An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 3, 2015 PMDA BRISTOL-MYERS SQUIBB K.K
March 25, 2011 FDA BRISTOL MYERS SQUIBB
July 13, 2011 EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 1856.55 21.43 762 18439 67362 50518561
Hypophysitis 1207.17 21.43 241 18960 1333 50584590
Colitis 1104.82 21.43 448 18753 38081 50547842
Immune-mediated enterocolitis 547.50 21.43 117 19084 943 50584980
Adrenal insufficiency 467.81 21.43 183 19018 14060 50571863
Intentional product use issue 420.80 21.43 296 18905 76622 50509301
Hypopituitarism 357.29 21.43 80 19121 817 50585106
Autoimmune colitis 326.88 21.43 66 19135 388 50585535
Death 319.49 21.43 495 18706 324884 50261039
Pneumonitis 296.12 21.43 167 19034 29343 50556580
Hypothyroidism 291.70 21.43 174 19027 33951 50551972
Immune-mediated hepatitis 271.10 21.43 64 19137 840 50585083
Hyperthyroidism 237.30 21.43 108 19093 12067 50573856
Thyroiditis 231.13 21.43 65 19136 1757 50584166
Lymphocytic hypophysitis 214.33 21.43 41 19160 173 50585750
Autoimmune hepatitis 213.37 21.43 87 19114 7432 50578491
Myocarditis 212.08 21.43 88 19113 7859 50578064
Type 1 diabetes mellitus 192.80 21.43 64 19137 3049 50582874
Diarrhoea 191.63 21.43 571 18630 587905 49998018
Fulminant type 1 diabetes mellitus 190.47 21.43 40 19161 293 50585630
Hepatic function abnormal 174.25 21.43 124 19077 32557 50553366
Enterocolitis 172.80 21.43 72 19129 6495 50579428
Hepatitis 169.21 21.43 120 19081 31333 50554590
Pyrexia 140.71 21.43 387 18814 379816 50206107
Immune-mediated lung disease 140.47 21.43 32 19169 355 50585568
Adrenocorticotropic hormone deficiency 135.07 21.43 29 19172 239 50585684
Immune-mediated thyroiditis 134.67 21.43 23 19178 41 50585882
Secondary adrenocortical insufficiency 132.45 21.43 38 19163 1105 50584818
Drug ineffective 122.33 21.43 81 19120 819252 49766671
Immune-mediated hepatic disorder 120.82 21.43 24 19177 128 50585795
Diabetic ketoacidosis 116.99 21.43 77 19124 17795 50568128
Myositis 116.77 21.43 58 19143 7862 50578061
Liver disorder 115.98 21.43 103 19098 37119 50548804
Hypothalamo-pituitary disorder 107.93 21.43 29 19172 658 50585265
Vitiligo 97.27 21.43 30 19171 1124 50584799
Meningitis aseptic 90.99 21.43 40 19161 4112 50581811
Prescribed overdose 90.96 21.43 61 19140 14539 50571384
Autoimmune thyroiditis 86.36 21.43 36 19165 3249 50582674
Metastases to central nervous system 84.70 21.43 53 19148 11229 50574694
Rash maculo-papular 81.54 21.43 73 19128 26568 50559355
Sepsis 77.80 21.43 162 19039 132763 50453160
Drug hypersensitivity 72.86 21.43 6 19195 251004 50334919
Myasthenia gravis 70.73 21.43 32 19169 3520 50582403
Rash 69.13 21.43 338 18863 437133 50148790
Joint swelling 68.15 21.43 7 19194 245279 50340644
Tumour pseudoprogression 67.48 21.43 16 19185 214 50585709
Lipase increased 66.33 21.43 41 19160 8500 50577423
Pain 65.70 21.43 74 19127 578829 50007094
Exposure via body fluid 65.67 21.43 18 19183 441 50585482
Immune-mediated myocarditis 64.28 21.43 13 19188 77 50585846
Drug intolerance 64.24 21.43 5 19196 219099 50366824
Immune-mediated encephalitis 63.31 21.43 13 19188 84 50585839
Intestinal perforation 58.68 21.43 41 19160 10438 50575485
Product dose omission issue 57.43 21.43 3 19198 183835 50402088
Drug interaction 57.28 21.43 5 19196 199616 50386307
Condition aggravated 56.65 21.43 21 19180 297037 50288886
Encephalitis 56.23 21.43 35 19166 7345 50578578
Drug-induced liver injury 56.13 21.43 61 19140 28034 50557889
Enteritis 55.39 21.43 34 19167 6961 50578962
Leukoderma 53.32 21.43 11 19190 73 50585850
Autoimmune arthritis 53.31 21.43 10 19191 37 50585886
Pleural effusion 53.24 21.43 104 19097 81350 50504573
Immune-mediated dermatitis 51.93 21.43 10 19191 44 50585879
Hyponatraemia 51.40 21.43 113 19088 96026 50489897
Adrenalitis 50.55 21.43 8 19193 6 50585917
Amylase increased 49.77 21.43 29 19172 5401 50580522
Arthropathy 48.02 21.43 3 19198 157903 50428020
Haemophagocytic lymphohistiocytosis 46.53 21.43 33 19168 8600 50577323
Autoimmune pancreatitis 46.52 21.43 12 19189 231 50585692
Immune-mediated adverse reaction 45.67 21.43 12 19189 249 50585674
Nephritis 45.62 21.43 20 19181 2042 50583881
Metastatic malignant melanoma 45.37 21.43 17 19184 1157 50584766
Immune-mediated nephritis 43.72 21.43 9 19192 59 50585864
Myasthenic syndrome 43.71 21.43 11 19190 191 50585732
Vogt-Koyanagi-Harada disease 43.48 21.43 10 19191 116 50585807
Uveitis 42.07 21.43 32 19169 9278 50576645
Adrenocortical insufficiency acute 41.95 21.43 17 19184 1427 50584496
Immune-mediated hypophysitis 41.54 21.43 7 19194 11 50585912
Nasopharyngitis 41.45 21.43 11 19190 192916 50393007
Neurofibrosarcoma 41.36 21.43 10 19191 146 50585777
Guillain-Barre syndrome 41.24 21.43 22 19179 3455 50582468
Aspartate aminotransferase increased 40.91 21.43 91 19110 77907 50508016
Encephalitis autoimmune 40.68 21.43 16 19185 1242 50584681
Peripheral swelling 40.17 21.43 14 19187 205922 50380001
Transaminases increased 39.93 21.43 51 19150 27773 50558150
Pregnancy on contraceptive 39.80 21.43 15 19186 1037 50584886
Duodenitis 39.67 21.43 21 19180 3247 50582676
Meningitis 39.14 21.43 26 19175 6095 50579828
Dehydration 38.27 21.43 136 19065 152313 50433610
Pancreatitis 37.55 21.43 62 19139 42552 50543371
Tumour pain 37.52 21.43 15 19186 1215 50584708
Thyroid disorder 37.33 21.43 34 19167 12643 50573280
Abdominal discomfort 36.95 21.43 21 19180 231620 50354303
Thyrotoxic crisis 36.94 21.43 13 19188 739 50585184
Endocrine disorder 36.35 21.43 12 19189 561 50585362
Sinusitis 36.12 21.43 10 19191 170548 50415375
Synovitis 35.79 21.43 3 19198 123862 50462061
Treatment failure 35.55 21.43 5 19196 137632 50448291
Swelling 35.34 21.43 16 19185 200856 50385067
Alopecia 35.26 21.43 25 19176 245022 50340901
Hypersensitivity 35.04 21.43 19 19182 215142 50370781
Autoimmune myocarditis 34.68 21.43 7 19194 41 50585882
Blood pressure increased 34.00 21.43 5 19196 133127 50452796
Hyperglycaemia 33.48 21.43 54 19147 36351 50549572
Iridocyclitis 33.17 21.43 16 19185 2033 50583890
Cortisol decreased 33.15 21.43 13 19188 1001 50584922
Hepatic failure 32.62 21.43 50 19151 32233 50553690
Fall 32.51 21.43 48 19153 334884 50251039
Adverse event 32.45 21.43 59 19142 43704 50542219
Glucocorticoid deficiency 32.21 21.43 9 19192 237 50585686
Large intestine perforation 32.20 21.43 25 19176 7469 50578454
Exposure during pregnancy 32.20 21.43 4 19197 121011 50464912
Decreased appetite 32.10 21.43 156 19045 200767 50385156
Acute kidney injury 31.51 21.43 170 19031 227888 50358035
Feeling abnormal 31.39 21.43 5 19196 125487 50460436
Cytokine release syndrome 31.15 21.43 26 19175 8608 50577315
Propionibacterium infection 30.69 21.43 6 19195 29 50585894
Meningoradiculitis 30.61 21.43 7 19194 79 50585844
Drug eruption 30.35 21.43 41 19160 23565 50562358
Diabetes mellitus 30.09 21.43 61 19140 48972 50536951
Autoimmune dermatitis 29.75 21.43 6 19195 35 50585888
Immune-mediated arthritis 29.60 21.43 6 19195 36 50585887
Embolism 29.41 21.43 23 19178 6945 50578978
Maternal exposure during pregnancy 29.25 21.43 12 19189 159766 50426157
Immune-mediated uveitis 29.24 21.43 5 19196 9 50585914
Alanine aminotransferase increased 28.61 21.43 86 19115 88273 50497650
Serous retinal detachment 28.00 21.43 8 19193 229 50585694
Dizziness 26.95 21.43 57 19144 346312 50239611
Gastritis 26.42 21.43 46 19155 32937 50552986
Rheumatoid arthritis 26.18 21.43 23 19178 202527 50383396
Erythema multiforme 26.11 21.43 24 19177 9026 50576897
Immune-mediated hyperthyroidism 25.78 21.43 5 19196 23 50585900
Primary hypothyroidism 25.60 21.43 6 19195 76 50585847
Autoimmune haemolytic anaemia 25.60 21.43 17 19184 3982 50581941
Gastrointestinal toxicity 25.48 21.43 18 19183 4659 50581264
Overdose 24.88 21.43 4 19197 99723 50486200
Pain in extremity 24.66 21.43 41 19160 272824 50313099
Pancreatic failure 24.35 21.43 10 19191 868 50585055
Metastases to lung 23.90 21.43 25 19176 10995 50574928
Autoimmune disorder 23.71 21.43 19 19182 5941 50579982
Cholangitis 23.52 21.43 17 19184 4562 50581361
Dermatitis 23.47 21.43 28 19173 14223 50571700
Hepatotoxicity 23.16 21.43 39 19162 27187 50558736
Musculoskeletal stiffness 22.95 21.43 10 19191 128471 50457452
Weight increased 22.58 21.43 26 19175 201865 50384058
Proctitis 22.31 21.43 12 19189 1916 50584007
Therapeutic product effect incomplete 22.10 21.43 4 19197 91511 50494412
Autoimmune neuropathy 21.97 21.43 4 19197 12 50585911
Neoplasm malignant 21.56 21.43 35 19166 23680 50562243

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 2298.15 17.99 1268 31838 72591 29468830
Colitis 1650.65 17.99 769 32337 30479 29510942
Hypophysitis 1591.44 17.99 382 32724 1588 29539833
Immune-mediated enterocolitis 748.42 17.99 202 32904 1451 29539970
Adrenal insufficiency 733.02 17.99 320 32786 10794 29530627
Intentional product use issue 590.94 17.99 441 32665 42057 29499364
Hypopituitarism 579.68 17.99 167 32939 1563 29539858
Pneumonitis 514.84 17.99 345 32761 27699 29513722
Autoimmune colitis 455.76 17.99 120 32986 773 29540648
Hypothyroidism 423.82 17.99 248 32858 15658 29525763
Autoimmune hepatitis 411.34 17.99 154 32952 3448 29537973
Immune-mediated hepatitis 400.61 17.99 122 32984 1405 29540016
Hyperthyroidism 342.43 17.99 175 32931 8433 29532988
Diarrhoea 335.48 17.99 969 32137 331729 29209692
Thyroiditis 316.92 17.99 108 32998 1820 29539601
Myocarditis 289.59 17.99 170 32936 10786 29530635
Lymphocytic hypophysitis 266.94 17.99 58 33048 134 29541287
Enterocolitis 254.93 17.99 132 32974 6534 29534887
Prescribed overdose 248.78 17.99 142 32964 8541 29532880
Secondary adrenocortical insufficiency 242.01 17.99 77 33029 1034 29540387
Hepatitis 234.81 17.99 191 32915 20592 29520829
Type 1 diabetes mellitus 233.80 17.99 103 33003 3541 29537880
Adrenocorticotropic hormone deficiency 196.67 17.99 57 33049 545 29540876
Fulminant type 1 diabetes mellitus 193.14 17.99 57 33049 584 29540837
Death 183.33 17.99 811 32295 341273 29200148
Rash 179.67 17.99 542 32564 189277 29352144
Drug interaction 177.62 17.99 11 33095 197374 29344047
Pyrexia 177.36 17.99 712 32394 286910 29254511
Liver disorder 176.53 17.99 185 32921 27564 29513857
Myositis 175.34 17.99 121 32985 10162 29531259
Hepatic function abnormal 170.74 17.99 215 32891 39044 29502377
Immune-mediated myocarditis 166.20 17.99 44 33062 290 29541131
Drug ineffective 164.91 17.99 102 33004 363068 29178353
Myasthenia gravis 154.83 17.99 74 33032 3077 29538344
Vitiligo 153.55 17.99 50 33056 726 29540695
Diabetic ketoacidosis 151.25 17.99 133 32973 15940 29525481
Metastases to central nervous system 143.44 17.99 93 33013 7038 29534383
Immune-mediated lung disease 141.95 17.99 47 33059 721 29540700
Adverse event 138.84 17.99 124 32982 15167 29526254
Hypothalamo-pituitary disorder 131.12 17.99 44 33062 705 29540716
Autoimmune thyroiditis 120.82 17.99 45 33061 991 29540430
Immune-mediated dermatitis 112.83 17.99 26 33080 86 29541335
Lipase increased 112.20 17.99 85 33021 8252 29533169
Uveitis 106.15 17.99 72 33034 5875 29535546
Immune-mediated hepatic disorder 100.47 17.99 30 33076 321 29541100
Toxicity to various agents 96.39 17.99 37 33069 173624 29367797
Intestinal perforation 90.60 17.99 74 33032 8012 29533409
Autoimmune nephritis 90.15 17.99 24 33082 162 29541259
Hyponatraemia 89.64 17.99 219 32887 67414 29474007
Nephritis 89.49 17.99 45 33061 2091 29539330
Large intestine perforation 83.85 17.99 68 33038 7288 29534133
Encephalitis 80.91 17.99 63 33043 6367 29535054
Interstitial lung disease 78.71 17.99 189 32917 57529 29483892
Autoimmune disorder 75.52 17.99 36 33070 1487 29539934
Endocrine disorder 72.56 17.99 22 33084 249 29541172
Tubulointerstitial nephritis 72.49 17.99 94 33012 17549 29523872
Adrenocortical insufficiency acute 70.99 17.99 33 33073 1287 29540134
Meningitis aseptic 68.41 17.99 39 33067 2337 29539084
Product dose omission issue 67.52 17.99 13 33093 96370 29445051
Overdose 67.25 17.99 6 33100 79813 29461608
Hyperglycaemia 67.10 17.99 130 32976 34157 29507264
Blood thyroid stimulating hormone decreased 66.99 17.99 35 33071 1763 29539658
Dermatitis 64.43 17.99 60 33046 7738 29533683
Thyroid disorder 63.49 17.99 39 33067 2683 29538738
Serous retinal detachment 63.08 17.99 22 33084 398 29541023
Blood corticotrophin decreased 62.71 17.99 17 33089 124 29541297
Facial paralysis 62.62 17.99 65 33041 9564 29531857
Guillain-Barre syndrome 60.29 17.99 48 33058 5010 29536411
Rash maculo-papular 60.13 17.99 102 33004 24187 29517234
Adrenal disorder 59.26 17.99 25 33081 771 29540650
Leukoderma 59.08 17.99 14 33092 54 29541367
Autoimmune pancreatitis 58.21 17.99 19 33087 278 29541143
Decreased appetite 56.83 17.99 316 32790 145026 29396395
Immune-mediated encephalitis 53.72 17.99 14 33092 86 29541335
Pemphigoid 52.60 17.99 53 33053 7528 29533893
Hypercalcaemia 52.44 17.99 68 33038 12691 29528730
Enteritis 51.81 17.99 50 33056 6741 29534680
Cortisol decreased 51.72 17.99 23 33083 808 29540613
Immune-mediated thyroiditis 51.33 17.99 12 33094 43 29541378
Condition aggravated 51.16 17.99 53 33053 146242 29395179
Tri-iodothyronine free decreased 51.12 17.99 12 33094 44 29541377
Immune-mediated adverse reaction 50.61 17.99 19 33087 428 29540993
Immune-mediated nephritis 49.94 17.99 15 33091 164 29541257
Amylase increased 48.26 17.99 43 33063 5237 29536184
Haemoglobin decreased 46.79 17.99 32 33074 108343 29433078
Prescribed underdose 44.35 17.99 49 33057 7737 29533684
Blood pressure increased 43.84 17.99 14 33092 73789 29467632
Fall 43.23 17.99 83 33023 177095 29364326
General physical health deterioration 43.10 17.99 228 32878 102629 29438792
Agitation 42.82 17.99 4 33102 51300 29490121
Drug hypersensitivity 42.40 17.99 12 33094 68394 29473027
Intracranial tumour haemorrhage 42.09 17.99 15 33091 290 29541131
Arthritis 41.97 17.99 89 33017 24930 29516491
Immune-mediated pancreatitis 41.72 17.99 10 33096 41 29541380
Aspartate aminotransferase increased 41.47 17.99 154 32952 59571 29481850
Erythema multiforme 41.28 17.99 47 33059 7670 29533751
Dizziness 41.14 17.99 95 33011 189589 29351832
Encephalitis autoimmune 40.82 17.99 17 33089 507 29540914
Autoimmune haemolytic anaemia 40.57 17.99 34 33072 3814 29537607
Immune-mediated hypophysitis 39.97 17.99 9 33097 26 29541395
Iridocyclitis 39.75 17.99 23 33083 1417 29540004
Tumour pseudoprogression 39.03 17.99 15 33091 361 29541060
Enterocolitis haemorrhagic 38.85 17.99 19 33087 831 29540590
Feeling abnormal 38.84 17.99 7 33099 54438 29486983
Dehydration 38.04 17.99 239 32867 114509 29426912
Immune-mediated myositis 37.47 17.99 23 33083 1580 29539841
Skin disorder 37.34 17.99 55 33051 11563 29529858
Haemophagocytic lymphohistiocytosis 37.09 17.99 52 33054 10452 29530969
Cardiac failure congestive 36.68 17.99 20 33086 76561 29464860
Somnolence 36.39 17.99 31 33075 93924 29447497
Immune-mediated hypothyroidism 36.30 17.99 10 33096 78 29541343
Silent thyroiditis 36.26 17.99 9 33097 44 29541377
Pruritus 36.04 17.99 239 32867 116610 29424811
Autoimmune neuropathy 35.93 17.99 9 33097 46 29541375
Alanine aminotransferase increased 35.92 17.99 166 32940 70778 29470643
Pancreatic enzymes increased 35.82 17.99 16 33090 568 29540853
Drug-induced liver injury 35.13 17.99 76 33030 21579 29519842
Joint swelling 34.09 17.99 7 33099 49623 29491798
Hepatotoxicity 34.03 17.99 67 33039 17800 29523621
Immune-mediated adrenal insuficiency 33.60 17.99 7 33099 12 29541409
Pulmonary toxicity 33.58 17.99 34 33072 4856 29536565
Anxiety 33.26 17.99 28 33078 85337 29456084
Bradycardia 33.13 17.99 16 33090 65613 29475808
Pituitary enlargement 32.90 17.99 7 33099 14 29541407
Pain in extremity 32.24 17.99 46 33060 110387 29431034
Sialoadenitis 32.13 17.99 14 33092 468 29540953
White blood cell count decreased 31.68 17.99 28 33078 83334 29458087
Hallucination 31.35 17.99 6 33100 44706 29496715
Weight increased 30.04 17.99 25 33081 76642 29464779
Chronic gastritis 29.98 17.99 18 33088 1188 29540233
Iris adhesions 29.75 17.99 11 33095 237 29541184
Transaminases increased 29.56 17.99 73 33033 22589 29518832
Aggression 29.05 17.99 3 33103 35538 29505883
Blood glucose increased 28.84 17.99 15 33091 58969 29482452
Myocardial infarction 28.35 17.99 50 33056 110246 29431175
Loss of consciousness 27.98 17.99 25 33081 74031 29467390
Thyroid function test abnormal 27.89 17.99 14 33092 648 29540773
Myasthenic syndrome 27.71 17.99 12 33094 395 29541026
Immune-mediated endocrinopathy 27.28 17.99 6 33100 15 29541406
Epistaxis 27.03 17.99 12 33094 51692 29489729
Immune-mediated uveitis 26.73 17.99 6 33100 17 29541404
Tremor 26.40 17.99 26 33080 73512 29467909
Radiation pneumonitis 26.23 17.99 21 33085 2208 29539213
Coma 26.21 17.99 6 33100 39444 29501977
Autoimmune arthritis 26.07 17.99 7 33099 49 29541372
Immune-mediated neuropathy 26.00 17.99 6 33100 20 29541401
Radiation necrosis 25.73 17.99 8 33098 99 29541322
Depression 25.31 17.99 35 33071 85112 29456309
Tumour associated fever 25.08 17.99 10 33096 266 29541155
Peripheral motor neuropathy 24.69 17.99 18 33088 1647 29539774
Orbital myositis 24.20 17.99 8 33098 122 29541299
Therapeutic product effect incomplete 24.15 17.99 7 33099 39298 29502123
Vogt-Koyanagi-Harada disease 23.52 17.99 7 33099 74 29541347
Peripheral swelling 23.50 17.99 22 33084 63717 29477704
Coronary artery disease 23.50 17.99 10 33096 44180 29497241
Immune thrombocytopenia 23.47 17.99 36 33070 7841 29533580
Pain 23.10 17.99 106 33000 171326 29370095
Bile duct stenosis 23.00 17.99 15 33091 1145 29540276
Angioedema 22.98 17.99 4 33102 31911 29509510
Autoimmune hypothyroidism 22.87 17.99 6 33100 38 29541383
Drug intolerance 22.63 17.99 13 33093 48366 29493055
Meningitis 22.55 17.99 26 33080 4299 29537122
Inappropriate schedule of product administration 22.20 17.99 11 33095 44461 29496960
Wheezing 22.19 17.99 5 33101 33235 29508186
International normalised ratio increased 22.11 17.99 11 33095 44361 29497060
Optic neuritis 22.05 17.99 22 33084 3087 29538334
Incorrect dose administered 21.94 17.99 5 33101 32979 29508442
Drug eruption 21.91 17.99 54 33052 16687 29524734
Adrenalitis 21.82 17.99 5 33101 16 29541405
Muscular weakness 21.63 17.99 131 32975 61921 29479500
Palpitations 21.57 17.99 5 33101 32599 29508822
Myelitis 21.31 17.99 12 33094 702 29540719
Disease progression 21.16 17.99 37 33069 81879 29459542
Muscle spasms 21.15 17.99 25 33081 65057 29476364
Immune-mediated cholangitis 21.12 17.99 6 33100 53 29541368
Spermatogenesis abnormal 21.12 17.99 6 33100 53 29541368
Thyroxine decreased 20.70 17.99 7 33099 115 29541306
Chest pain 20.48 17.99 61 33045 111912 29429509
Parvovirus infection 20.41 17.99 10 33096 439 29540982
Hypertension 20.28 17.99 65 33041 116549 29424872
Melanoma recurrent 20.26 17.99 7 33099 123 29541298
Treatment failure 20.23 17.99 8 33098 36931 29504490
Polymyalgia rheumatica 20.05 17.99 14 33092 1197 29540224
Opsoclonus myoclonus 19.86 17.99 6 33100 67 29541354
Blood corticotrophin increased 19.86 17.99 6 33100 67 29541354
Autoimmune dermatitis 19.53 17.99 4 33102 6 29541415
Metastases to skin 19.41 17.99 9 33097 349 29541072
Polyarthritis 19.38 17.99 23 33083 3922 29537499
Tachycardia 19.35 17.99 32 33074 72378 29469043
Chest discomfort 19.27 17.99 14 33092 45969 29495452
Fatigue 18.96 17.99 476 32630 316345 29225076
Thyroxine free decreased 18.92 17.99 8 33098 248 29541173
Heart rate increased 18.88 17.99 10 33096 38928 29502493
Prostate cancer 18.82 17.99 3 33103 25524 29515897
Brain oedema 18.81 17.99 42 33064 12178 29529243
Gastrointestinal toxicity 18.77 17.99 17 33089 2114 29539307
Hyperhidrosis 18.70 17.99 27 33079 64513 29476908
Nephrolithiasis 18.63 17.99 3 33103 25331 29516090
Primary hypothyroidism 18.62 17.99 5 33101 35 29541386
Thrombophlebitis migrans 18.56 17.99 6 33100 85 29541336
Oxygen saturation decreased 18.42 17.99 14 33092 44923 29496498
Nasopharyngitis 18.25 17.99 24 33082 59641 29481780
Heart rate decreased 18.21 17.99 3 33103 24909 29516512
Transient acantholytic dermatosis 18.18 17.99 6 33100 91 29541330
Haematocrit decreased 18.14 17.99 5 33101 29017 29512404

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 3762.97 17.95 1770 45562 111101 64340299
Hypophysitis 2586.99 17.95 585 46747 2974 64448426
Colitis 2367.21 17.95 1053 46279 57621 64393779
Adrenal insufficiency 1132.92 17.95 473 46859 22014 64429386
Immune-mediated enterocolitis 1078.92 17.95 273 47059 2383 64449017
Hypopituitarism 901.80 17.95 237 47095 2436 64448964
Pneumonitis 743.76 17.95 462 46870 49903 64401497
Autoimmune colitis 706.03 17.95 171 47161 1220 64450180
Hypothyroidism 668.81 17.95 399 46933 40058 64411342
Immune-mediated hepatitis 616.44 17.95 173 47159 2316 64449084
Intentional product use issue 611.22 17.95 528 46804 94836 64356564
Hyperthyroidism 556.09 17.95 270 47062 17909 64433491
Thyroiditis 543.93 17.95 171 47161 3453 64447947
Autoimmune hepatitis 527.36 17.95 218 47114 9866 64441534
Myocarditis 461.49 17.95 233 47099 16810 64434590
Diarrhoea 436.59 17.95 1337 45995 721367 63730033
Type 1 diabetes mellitus 423.73 17.95 159 47173 5546 64445854
Lymphocytic hypophysitis 412.08 17.95 88 47244 322 64451078
Enterocolitis 393.28 17.95 187 47145 11831 64439569
Secondary adrenocortical insufficiency 365.90 17.95 114 47218 2231 64449169
Fulminant type 1 diabetes mellitus 365.39 17.95 96 47236 984 64450416
Hepatic function abnormal 344.32 17.95 322 47010 63991 64387409
Pyrexia 318.15 17.95 1014 46318 557630 63893770
Hepatitis 313.34 17.95 263 47069 45319 64406081
Adrenocorticotropic hormone deficiency 312.93 17.95 81 47251 779 64450621
Liver disorder 287.22 17.95 268 47064 53083 64398317
Myositis 284.75 17.95 167 47165 16210 64435190
Diabetic ketoacidosis 260.17 17.95 198 47134 29647 64421753
Immune-mediated lung disease 259.16 17.95 75 47257 1127 64450273
Death 253.52 17.95 853 46479 481852 63969548
Immune-mediated myocarditis 230.97 17.95 56 47276 401 64450999
Vitiligo 230.64 17.95 75 47257 1693 64449707
Hypothalamo-pituitary disorder 228.91 17.95 66 47266 978 64450422
Drug ineffective 227.12 17.95 172 47160 840075 63611325
Myasthenia gravis 214.74 17.95 98 47234 5640 64445760
Immune-mediated hepatic disorder 202.02 17.95 52 47280 488 64450912
Drug interaction 194.62 17.95 20 47312 362063 64089337
Metastases to central nervous system 190.99 17.95 122 47210 13790 64437610
Prescribed overdose 190.78 17.95 141 47191 20190 64431210
Autoimmune thyroiditis 186.87 17.95 77 47255 3451 64447949
Lipase increased 182.25 17.95 120 47212 14282 64437118
Immune-mediated thyroiditis 174.00 17.95 35 47297 87 64451313
Immune-mediated dermatitis 169.15 17.95 36 47296 129 64451271
Rash 168.05 17.95 723 46609 457826 63993574
Toxicity to various agents 151.41 17.95 40 47292 363473 64087927
Meningitis aseptic 151.14 17.95 77 47255 5653 64445747
Hyponatraemia 133.30 17.95 319 47013 148020 64303380
Rash maculo-papular 132.60 17.95 168 47164 46858 64404542
Uveitis 132.59 17.95 94 47238 12614 64438786
Encephalitis 124.30 17.95 90 47242 12481 64438919
Interstitial lung disease 121.91 17.95 240 47092 97492 64353908
Joint swelling 120.69 17.95 10 47322 215372 64236028
Drug hypersensitivity 120.55 17.95 16 47316 237799 64213601
Intestinal perforation 119.10 17.95 95 47237 15218 64436182
Leukoderma 116.72 17.95 26 47306 121 64451279
Large intestine perforation 115.07 17.95 86 47246 12518 64438882
Condition aggravated 111.16 17.95 68 47264 372358 64079042
Hyperglycaemia 108.60 17.95 175 47157 60793 64390607
Enteritis 107.14 17.95 81 47251 11996 64439404
Tumour pseudoprogression 106.49 17.95 31 47301 476 64450924
Adrenocortical insufficiency acute 106.13 17.95 47 47285 2518 64448882
Pain 104.49 17.95 153 47179 553358 63898042
Immune-mediated encephalitis 104.36 17.95 27 47305 259 64451141
Product dose omission issue 103.89 17.95 11 47321 194736 64256664
Nephritis 99.09 17.95 50 47282 3596 64447804
Guillain-Barre syndrome 97.52 17.95 64 47268 7571 64443829
Overdose 96.46 17.95 5 47327 159561 64291839
Decreased appetite 96.24 17.95 435 46897 280854 64170546
Autoimmune pancreatitis 93.18 17.95 29 47303 565 64450835
Tubulointerstitial nephritis 92.84 17.95 114 47218 30795 64420605
Drug intolerance 92.09 17.95 14 47318 187978 64263422
Amylase increased 90.47 17.95 67 47265 9618 64441782
Immune-mediated nephritis 89.22 17.95 24 47308 271 64451129
Endocrine disorder 88.57 17.95 29 47303 669 64450731
Serous retinal detachment 88.57 17.95 29 47303 669 64450731
Dehydration 84.67 17.95 349 46983 216414 64234986
Haemophagocytic lymphohistiocytosis 84.35 17.95 83 47249 17526 64433874
Aspartate aminotransferase increased 84.22 17.95 235 47097 119553 64331847
Cortisol decreased 83.42 17.95 35 47297 1642 64449758
Autoimmune nephritis 82.85 17.95 26 47306 521 64450879
Blood pressure increased 81.93 17.95 14 47318 172538 64278862
Peripheral swelling 81.49 17.95 26 47306 209127 64242273
Immune-mediated hypophysitis 79.76 17.95 16 47316 39 64451361
Sepsis 75.59 17.95 352 46980 229989 64221411
Autoimmune disorder 74.88 17.95 49 47283 5767 64445633
Blood corticotrophin decreased 74.33 17.95 22 47310 359 64451041
Autoimmune haemolytic anaemia 70.73 17.95 51 47281 7025 64444375
Facial paralysis 70.40 17.95 78 47254 18888 64432512
Nasopharyngitis 70.20 17.95 28 47304 196045 64255355
Dermatitis 70.14 17.95 76 47256 17953 64433447
Alanine aminotransferase increased 70.12 17.95 243 47089 138788 64312612
Thyroid disorder 69.23 17.95 62 47270 11630 64439770
Fall 68.48 17.95 126 47206 416700 64034700
Adrenal disorder 68.05 17.95 30 47302 1590 64449810
Pleural effusion 68.04 17.95 226 47106 126333 64325067
Drug-induced liver injury 68.03 17.95 124 47208 47519 64403881
Erythema multiforme 67.85 17.95 70 47262 15631 64435769
Weight increased 67.80 17.95 36 47296 213312 64238088
Feeling abnormal 67.63 17.95 9 47323 133593 64317807
Encephalitis autoimmune 66.80 17.95 31 47301 1853 64449547
Immune-mediated adverse reaction 66.64 17.95 24 47308 743 64450657
Iridocyclitis 66.31 17.95 36 47296 3009 64448391
Autoimmune arthritis 66.30 17.95 16 47316 112 64451288
Blood thyroid stimulating hormone decreased 64.75 17.95 43 47289 5187 64446213
Arthropathy 64.06 17.95 7 47325 120960 64330440
Swelling 64.05 17.95 19 47313 160199 64291201
Dizziness 63.82 17.95 138 47194 430025 64021375
Transaminases increased 62.33 17.95 115 47217 44479 64406921
Vogt-Koyanagi-Harada disease 58.52 17.95 16 47316 193 64451207
Tri-iodothyronine free decreased 58.21 17.95 18 47314 343 64451057
Meningitis 57.06 17.95 48 47284 8281 64443119
Pain in extremity 56.83 17.95 84 47248 303001 64148399
Immune-mediated hypothyroidism 56.80 17.95 15 47317 157 64451243
Pemphigoid 56.30 17.95 58 47274 12928 64438472
Acute kidney injury 56.12 17.95 539 46793 448701 64002699
Adrenalitis 56.00 17.95 11 47321 23 64451377
Myasthenic syndrome 55.35 17.95 20 47312 625 64450775
Prescribed underdose 54.99 17.95 67 47265 17948 64433452
Immune-mediated uveitis 54.50 17.95 11 47321 28 64451372
Treatment failure 54.30 17.95 10 47322 116806 64334594
General physical health deterioration 54.05 17.95 294 47038 204131 64247269
Hypercalcaemia 52.97 17.95 88 47244 31328 64420072
Alopecia 52.57 17.95 28 47304 165662 64285738
Hepatotoxicity 52.05 17.95 100 47232 39862 64411538
Synovitis 51.80 17.95 6 47326 99084 64352316
Pancreatitis 51.12 17.95 126 47206 59481 64391919
Enterocolitis haemorrhagic 50.46 17.95 26 47306 1954 64449446
Sinusitis 50.35 17.95 22 47310 145906 64305494
Hepatic failure 49.54 17.95 119 47213 55275 64396125
Hypersensitivity 49.25 17.95 43 47289 196409 64254991
Immune-mediated pancreatitis 48.66 17.95 12 47320 93 64451307
Neoplasm malignant 48.28 17.95 74 47258 24614 64426786
Therapeutic product effect incomplete 47.79 17.95 9 47323 103473 64347927
Intracranial tumour haemorrhage 47.21 17.95 16 47316 412 64450988
Abdominal discomfort 46.81 17.95 39 47293 182283 64269117
Diabetes mellitus 46.28 17.95 130 47202 66344 64385056
Haemoglobin decreased 46.17 17.95 45 47287 195018 64256382
Autoimmune myocarditis 45.71 17.95 14 47318 258 64451142
Autoimmune neuropathy 45.71 17.95 11 47321 76 64451324
Bradycardia 45.48 17.95 15 47317 118204 64333196
Tumour pain 45.31 17.95 24 47308 1909 64449491
Systemic lupus erythematosus 45.16 17.95 3 47329 77609 64373791
Musculoskeletal stiffness 45.06 17.95 17 47315 123189 64328211
Palpitations 44.37 17.95 11 47321 104477 64346923
Silent thyroiditis 44.17 17.95 12 47320 141 64451259
Oxygen saturation decreased 44.14 17.95 12 47320 107164 64344236
Drug eruption 42.92 17.95 87 47245 36049 64415351
Maternal exposure during pregnancy 42.90 17.95 9 47323 95875 64355525
Duodenitis 42.41 17.95 37 47295 6704 64444696
Exposure during pregnancy 42.40 17.95 4 47328 77671 64373729
Exposure via body fluid 42.22 17.95 13 47319 244 64451156
Immune-mediated adrenal insuficiency 41.31 17.95 8 47324 15 64451385
Immune-mediated myositis 40.55 17.95 25 47307 2653 64448747
Meningoradiculitis 40.28 17.95 11 47321 132 64451268
Loss of consciousness 40.27 17.95 30 47302 148335 64303065
Agitation 40.14 17.95 8 47324 88359 64363041
Cytokine release syndrome 40.12 17.95 62 47270 20767 64430633
Cardiac failure congestive 40.06 17.95 23 47309 130557 64320843
Embolism 39.79 17.95 47 47285 12188 64439212
Disseminated intravascular coagulation 39.76 17.95 79 47253 32269 64419131
Wound 39.06 17.95 5 47327 76472 64374928
Tremor 38.93 17.95 31 47301 148199 64303201
Asthma 38.58 17.95 11 47321 95214 64356186
Chronic gastritis 38.58 17.95 26 47306 3214 64448186
Skin disorder 38.19 17.95 71 47261 27609 64423791
Anxiety 38.11 17.95 56 47276 202593 64248807
Rheumatoid arthritis 37.62 17.95 39 47293 164255 64287145
Gastritis 37.50 17.95 91 47241 42527 64408873
Wheezing 37.22 17.95 7 47325 80572 64370828
Pancreatic enzymes increased 37.19 17.95 18 47314 1183 64450217
Product use issue 37.07 17.95 34 47298 151681 64299719
Metastatic malignant melanoma 36.66 17.95 23 47309 2518 64448882
Immune thrombocytopenia 36.52 17.95 50 47282 15016 64436384
Primary hypothyroidism 36.39 17.95 10 47322 123 64451277
Brain oedema 36.10 17.95 61 47271 22014 64429386
Cholangitis 35.97 17.95 42 47290 10760 64440640
Radiation pneumonitis 35.60 17.95 25 47307 3303 64448097
Suicidal ideation 34.84 17.95 4 47328 66538 64384862
Orbital myositis 34.63 17.95 10 47322 149 64451251
Metastases to lung 34.53 17.95 49 47283 15215 64436185
Immune-mediated arthritis 33.75 17.95 9 47323 98 64451302
Pituitary enlargement 33.40 17.95 8 47324 54 64451346
Immune-mediated cholangitis 33.35 17.95 9 47323 103 64451297
Mobility decreased 32.83 17.95 11 47321 85829 64365571
Fluid retention 32.72 17.95 3 47329 59603 64391797
Myelitis 32.69 17.95 20 47312 2094 64449306
Glucocorticoid deficiency 32.41 17.95 13 47319 543 64450857
Thyrotoxic crisis 32.38 17.95 16 47316 1100 64450300
Heart rate increased 32.29 17.95 16 47316 98659 64352741
Loss of personal independence in daily activities 32.00 17.95 7 47325 72447 64378953
Neurofibrosarcoma 31.74 17.95 10 47322 203 64451197
Angioedema 31.67 17.95 4 47328 61817 64389583
Spermatogenesis abnormal 31.43 17.95 6 47326 10 64451390
Pulmonary toxicity 31.41 17.95 35 47297 8526 64442874
Radiation necrosis 31.16 17.95 11 47321 321 64451079
Pregnancy on contraceptive 31.14 17.95 14 47318 777 64450623
Peripheral motor neuropathy 31.05 17.95 22 47310 2948 64448452
Immune-mediated hyperthyroidism 31.01 17.95 7 47325 35 64451365
Blood corticotrophin increased 30.81 17.95 9 47323 140 64451260
Muscle spasms 30.59 17.95 35 47297 140988 64310412
Coma 30.54 17.95 13 47319 87602 64363798
Blood glucose increased 30.47 17.95 17 47315 98056 64353344
Osteoarthritis 30.35 17.95 5 47327 63331 64388069
Autoimmune dermatitis 30.08 17.95 7 47325 41 64451359
Metastases to meninges 29.77 17.95 21 47311 2794 64448606
Heart rate decreased 29.62 17.95 3 47329 55064 64396336
Gait disturbance 29.13 17.95 51 47281 172104 64279296
Gastrointestinal toxicity 29.11 17.95 27 47305 5295 64446105
Lichenoid keratosis 28.77 17.95 22 47310 3312 64448088
Depression 28.63 17.95 57 47275 183234 64268166
Pemphigus 28.63 17.95 5 47327 60696 64390704
Hallucination 28.41 17.95 9 47323 72779 64378621
Chest discomfort 28.38 17.95 26 47306 116080 64335320
Pancreatic failure 28.33 17.95 16 47316 1444 64449956
Immune-mediated encephalopathy 28.30 17.95 6 47326 21 64451379
Bile duct stenosis 27.90 17.95 17 47315 1767 64449633
Immune-mediated endocrinopathy 27.47 17.95 6 47326 25 64451375
Arthritis 27.36 17.95 128 47204 83686 64367714
Chest pain 27.06 17.95 86 47246 235894 64215506
Gastrointestinal perforation 26.78 17.95 26 47306 5398 64446002
Sialoadenitis 26.67 17.95 16 47316 1617 64449783
Incorrect dose administered 26.57 17.95 6 47326 60759 64390641
Metastases to liver 26.50 17.95 56 47276 23885 64427515
Gastrooesophageal reflux disease 26.43 17.95 14 47318 83129 64368271
Somnolence 26.42 17.95 70 47262 203575 64247825
Inappropriate schedule of product administration 25.90 17.95 18 47314 92268 64359132
Nasal congestion 25.87 17.95 6 47326 59652 64391748
Sarcoidosis 25.83 17.95 27 47305 6119 64445281
Tumour haemorrhage 25.74 17.95 21 47311 3472 64447928
White blood cell count decreased 25.59 17.95 48 47284 157789 64293611
Tumour associated fever 25.22 17.95 11 47321 568 64450832
Discomfort 25.15 17.95 14 47318 80864 64370536
Contusion 25.03 17.95 28 47304 113937 64337463
Polyarthritis 24.70 17.95 33 47299 9682 64441718
General physical condition abnormal 24.70 17.95 25 47307 5457 64445943
Tumour lysis syndrome 24.52 17.95 48 47284 19392 64432008
Thrombophlebitis migrans 24.47 17.95 9 47323 296 64451104
Optic neuritis 24.47 17.95 30 47302 8086 64443314
Achromotrichia acquired 24.43 17.95 5 47327 14 64451386
Unresponsive to stimuli 24.10 17.95 4 47328 50389 64401011
Muscular weakness 24.05 17.95 168 47164 127170 64324230
Migraine 24.02 17.95 8 47324 62669 64388731
Medication error 23.82 17.95 4 47328 49962 64401438
Blister 23.79 17.95 15 47317 80952 64370448
Respiratory arrest 23.64 17.95 5 47327 52980 64398420
Burning sensation 23.62 17.95 4 47328 49660 64401740
Hypertension 23.52 17.95 104 47228 259157 64192243
Autoimmune lung disease 23.47 17.95 5 47327 18 64451382
Insomnia 23.45 17.95 71 47261 197765 64253635
Myocardial infarction 23.06 17.95 55 47277 165766 64285634
Demyelinating polyneuropathy 22.91 17.95 14 47318 1462 64449938
Balance disorder 22.73 17.95 17 47315 83909 64367491
Influenza 22.50 17.95 27 47305 106504 64344896
Polymyalgia rheumatica 22.27 17.95 19 47313 3340 64448060
Endocrine toxicity 22.10 17.95 4 47328 4 64451396
Immune-mediated neuropathy 21.99 17.95 5 47327 26 64451374
Nephrolithiasis 21.96 17.95 3 47329 43680 64407720
Treatment noncompliance 21.83 17.95 3 47329 43479 64407921
Parvovirus infection 21.77 17.95 10 47322 584 64450816
Epistaxis 21.67 17.95 24 47308 98107 64353293
Giant cell arteritis 21.66 17.95 16 47316 2287 64449113
Electrocardiogram QT prolonged 21.63 17.95 16 47316 79432 64371968
Hypoalbuminaemia 21.52 17.95 43 47289 17631 64433769
Cytomegalovirus enterocolitis 21.41 17.95 13 47319 1342 64450058
Aggression 21.39 17.95 4 47328 46228 64405172
Thyroxine free decreased 21.28 17.95 11 47321 832 64450568
Primary adrenal insufficiency 20.86 17.95 6 47326 88 64451312
Autoimmune hypothyroidism 20.77 17.95 7 47325 177 64451223
Propionibacterium infection 20.61 17.95 8 47324 306 64451094
Melanoma recurrent 20.24 17.95 7 47325 192 64451208
Eosinophilic fasciitis 19.93 17.95 7 47325 201 64451199
Oesophagitis 19.90 17.95 47 47285 21583 64429817
Blood potassium decreased 19.78 17.95 3 47329 40396 64411004
Diarrhoea haemorrhagic 19.67 17.95 32 47300 11195 64440205
Osteonecrosis of jaw 19.40 17.95 3 47329 39822 64411578
Hyperhidrosis 19.37 17.95 39 47293 124881 64326519
Polymyositis 19.35 17.95 16 47316 2694 64448706
Peripheral sensory neuropathy 19.35 17.95 32 47300 11346 64440054
Hypogonadism 19.16 17.95 11 47321 1024 64450376
Gastroenteritis eosinophilic 19.13 17.95 7 47325 227 64451173
Arthralgia 19.13 17.95 220 47112 442040 64009360
Radiation skin injury 19.09 17.95 12 47320 1318 64450082
Immune-mediated renal disorder 18.87 17.95 5 47327 53 64451347
Flushing 18.76 17.95 18 47314 78630 64372770
Pancreatic atrophy 18.74 17.95 8 47324 392 64451008
Osteoporosis 18.71 17.95 4 47328 42076 64409324
Immune-mediated cystitis 18.65 17.95 3 47329 0 64451400
Retinal melanoma 18.65 17.95 3 47329 0 64451400
Tumour embolism 18.64 17.95 6 47326 131 64451269
Bronchitis 18.58 17.95 32 47300 108711 64342689
Autoimmune neutropenia 18.40 17.95 8 47324 410 64450990
Pericardial effusion 18.38 17.95 67 47265 39187 64412213
Tachycardia 18.21 17.95 53 47279 149526 64301874
Coronary artery disease 18.02 17.95 11 47321 60422 64390978

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000082082 Immune Checkpoint Inhibitors
FDA PE N0000182157 Increased T Lymphocyte Activation
FDA MoA N0000182634 CTLA-4-directed Antibody Interactions
FDA EPC N0000182635 CTLA-4-directed Blocking Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Unresectable advanced or recurrent malignant pleural mesothelioma indication 254645002 DOID:7474
Metastatic malignant melanoma indication 443493003
Renal cell carcinoma indication 702391001 DOID:4450
Microsatellite instability-high colorectal cancer indication 737058005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cytotoxic T-lymphocyte protein 4 Surface antigen ANTIBODY BINDING UNKNOWN DRUG LABEL

External reference:

IDSource
D04603 KEGG_DRUG
4030653 VUID
N0000182641 NUI
4030653 VANDF
CHEMBL1789844 ChEMBL_ID
6888 IUPHAR_LIGAND_ID
8568 INN_ID
DB06186 DRUGBANK_ID
6T8C155666 UNII
1094833 RXNORM
180596 MMSL
27014 MMSL
d07565 MMSL
697995005 SNOMEDCT_US
704649006 SNOMEDCT_US
D000074324 MESH_DESCRIPTOR_UI
C1367202 UMLSCUI
013688 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
YERVOY HUMAN PRESCRIPTION DRUG LABEL 1 0003-2327 INJECTION 5 mg INTRAVENOUS BLA 25 sections
YERVOY HUMAN PRESCRIPTION DRUG LABEL 1 0003-2327 INJECTION 5 mg INTRAVENOUS BLA 25 sections
YERVOY HUMAN PRESCRIPTION DRUG LABEL 1 0003-2328 INJECTION 5 mg INTRAVENOUS BLA 25 sections
YERVOY HUMAN PRESCRIPTION DRUG LABEL 1 0003-2328 INJECTION 5 mg INTRAVENOUS BLA 25 sections